Most cited papers from Institut Sainte Catherine

Institut Sainte Catherine

What are the most cited papers from Institut Sainte Catherine?

The most cited paper from Institut Sainte Catherine is "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial" (Axel F. Grothey, Eric Van Cutsem, Alberto Felice Sobrero et al., 2012), with 2,934 citations. Next come "Chemotherapy with Preoperative Radiotherapy in Rectal Cancer" (2,734) and "Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib" (1,103).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 110 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Axel F. Grothey, Eric Van Cutsem, Alberto Felice Sobrero et al. · The Lancet	21 Nov 2012	2,934
2	Chemotherapy with Preoperative Radiotherapy in Rectal Cancer Jean-François Bosset, Laurence Collette, G. Calais et al. · New England Journal of Medicine Open access	13 Sep 2006	2,734
3	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib Pascal R. Hammel, F. Huguet, Jean‐Luc Van Laethem et al. · JAMA	3 May 2016	1,103
4	Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study Jean-François Bosset, G. Calais, Laurent Mineur et al. · The Lancet Oncology	16 Jan 2014	741
5	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study Thomas Bachelot, C. Bourgier, Claire Cropet et al. · Journal of Clinical Oncology Open access	8 May 2012	712
6	Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study Bruno Chauffert, F. Mornex, F. Bonnetain et al. · Annals of Oncology Open access	9 May 2008	699
7	Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation Y. Pointreau, P. Garaud, Sophie CHAPET et al. · JNCI Journal of the National Cancer Institute	24 Mar 2009	574
8	Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients Fabrice Denis, Claire Lethrosne, Nicolas Pourel et al. · JNCI Journal of the National Cancer Institute Open access	15 Feb 2017	519
9	70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial V. Beckendorf, Stephane Gilles Guerif, É. Le Prisé et al. · International Journal of Radiation OncologyBiologyPhysics	15 Dec 2010	459
10	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group Benjamin Lacas et al. · Radiotherapy and Oncology ReviewOpen access105 authors	27 Jan 2021	391
11	Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial Jean Bourhis et al. · The Lancet Oncology	18 Jan 2012	388
12	Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia Cells Wenlin Shao, Mirco Fanelli, Fabiana Fosca Ferrara et al. · JNCI Journal of the National Cancer Institute Open access	21 Jan 1998	357
13	Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial François‐Clément Bidard et al. · The Lancet Oncology Open access119 authors	29 Sep 2022	349
14	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer Dominique Farge, Henri Bounameaux, Benjamin Brenner et al. · The Lancet Oncology Open access	Oct 2016	348
15	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary Valentı́n Fuster et al. · Circulation	3 Aug 2006	348
16	6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology	11 Jun 2013	343
17	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial Josep M. Tabernero, Heinz‐Josef Lenz, Salvatore Siena et al. · The Lancet Oncology Open access	13 Jul 2015	330
18	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review Élisabeth Luporsi et al. · Breast Cancer Research and Treatment Open access	2 Nov 2011	326
19	Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer P. Fumoleau, R. Largillier, Christine Clippe et al. · European Journal of Cancer	22 Dec 2003	308
20	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) Herve R. Bonnefoi et al. · Annals of Oncology Open access	7 Apr 2016	288
21	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial Cecile Le Pechoux et al. · The Lancet Oncology	15 Dec 2021	269
22	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Karim S. Fizazi et al. · The Lancet Oncology	29 May 2015	242
23	Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis Arlindo Rebelo Ferreira et al. · Annals of Oncology Open access	29 Aug 2019	230
24	Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems Fabrice Denis, Pascal Garaud, É. Bardet et al. · International Journal of Radiation OncologyBiologyPhysics	28 Dec 2002	228
25	A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) Marc Ychou, Jean‐Luc Raoul, Jean‐Yves Douillard et al. · Annals of Oncology Open access	29 Jan 2009	202
26	Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy John M. Kurtz, Jocelyne Jacquemier, Robert Amalric et al. · Cancer	15 Apr 1990	197
27	Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial Yungan Tao et al. · Annals of Oncology Open access	28 Oct 2022	192
28	Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial François‐Clément Bidard, F. Huguet, Christophe Louvet et al. · Annals of Oncology Open access	15 May 2013	192
29	Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial Jean‐Pierre Gérard, Nicolas N. Barbet, Renaud Schiappa et al. · The Lancet. Gastroenterology & hepatology Open access	16 Feb 2023	187
30	Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases B. Cutuli, C. Cohen-Solal Le-Nir, D. Serin et al. · Critical Reviews in Oncology/Hematology	13 May 2009	183
31	Long-Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation Guillaume Janoray, Y. Pointreau, Pascal Garaud et al. · JNCI Journal of the National Cancer Institute Open access	16 Dec 2015	182
32	A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02) M. Frikha, Anne Auperin, Yungan Tao et al. · Annals of Oncology Open access	5 Dec 2017	179
33	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer Paul Henri Cottu et al. · Annals of Oncology Open access	10 Oct 2018	174
34	Genomics to select treatment for patients with metastatic breast cancer Fabrice André et al. · Nature	7 Sep 2022	171
35	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study Eric HACHULLA, Pierre‐Yves Hatron, Patrick Carpentier et al. · Annals of the Rheumatic Diseases Open access	20 May 2015	165
36	The effect of fluoxetine on anxiety and depression symptoms in cancer patients Darius Razavi, J.‐F. Allilaire, Mark A. Smith et al. · Acta Psychiatrica Scandinavica	Sep 1996	165
37	Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study Mahmut Özsahin, A. Zouhair, S. Villà et al. · European Journal of Cancer Open access	May 1999	164
38	Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial Thomas Bachelot et al. · Nature Medicine	18 Jan 2021	161
39	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study Franck Pagès et al. · Annals of Oncology Open access	12 Apr 2020	155
40	Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab Julien Taı̈eb, Aziz Zaanan, Karine Le Malicot et al. · JAMA Oncology	15 Jan 2016	153
41	Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study Beat J. K. Thurlimann, Robert Paridaens, D. Serin et al. · European Journal of Cancer	Oct 1997	145
42	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial Benoît You et al. · Clinical Cancer Research	24 Mar 2020	141
43	Outcome and prognostic factors in orbital lymphoma Sylvie Martinet, Mahmut Özsahin, Yazid Belkacémi et al. · International Journal of Radiation OncologyBiologyPhysics	Mar 2003	135
44	Natural Killer cells at the frontline in the fight against cancer Loïs Coënon, Mannon Geindreau, François Ghiringhelli et al. · Cell Death and Disease Open access	23 Aug 2024	134
45	Impact of Intensity-Modulated Radiotherapy on Health-Related Quality of Life for Head and Neck Cancer Patients: Matched-Pair Comparison with Conventional Radiotherapy P. Gräff, M. Lapeyre, Emmanuel Désandes et al. · International Journal of Radiation OncologyBiologyPhysics	8 Feb 2007	133
46	Intensity-modulated radiotherapy in head and neck cancer: Results of the prospective study GORTEC 2004–03 I. Planas Toledano, P. Gräff, Antoine Serre et al. · Radiotherapy and Oncology	31 Jan 2012	132
47	Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study Xu-Shan Sun et al. · The Lancet Oncology	3 Aug 2020	130
48	6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier B. Pivot et al. · The Lancet Open access346 authors	Jun 2019	129
49	Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program Antoine Adenis, Christelle de la Fouchardière, Bernard Paule et al. · BMC Cancer Open access	7 Jul 2016	129
50	Axillary web syndrome after axillary dissection in breast cancer: a prospective study María Torres-Lacomba, Orlando Mayoral del Moral, José Luís Coperias Zazo et al. · Breast Cancer Research and Treatment Open access	20 Mar 2009	129

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.